Treatment options in severe fungal asthma and allergic bronchopulmonary aspergillosis.

[allergic bronchopulmonary aspergillosis]

Severe asthma with fungal sensitisation and allergic bronchopulmonary aspergillosis encompass two closely related subgroups of patients with severe allergic asthma . Pulmonary disease is due to pronounced host inflammatory responses to noninvasive subclinical endobronchial infection with filamentous fungi , usually Aspergillus fumigatus . These patients usually do not achieve satisfactory disease control with conventional treatment of severe asthma , i .e . high -dose inhaled corticosteroids and long -acting bronchodilators . Although prolonged systemic corticosteroids are effective , they carry a substantial toxicity profile . Supplementary or alternative therapies have primarily focused on use of antifungal agents including oral triazoles and inhaled amphotericin B . Immunomodulation with omalizumab , a humanised anti-IgE monoclonal antibody , or "pulse " monthly high -dose intravenous corticosteroid , has also been employed . This article considers the experience with these approaches , with emphasis on recent clinical trials .

Diseases
Validation

Diseases presenting "pronounced host inflammatory responses to noninvasive subclinical endobronchial infection with filamentous fungi" symptom

allergic bronchopulmonary aspergillosis

You can validate or delete this automatically detected symptom